Thermo Fisher Launches New Testing Service for Kidney Transplant Recipients

Thermo Fisher Scientific has announced the launch of the CXCL10 testing service, which will assist in the management of kidney transplant patients. The testing service is intended to make post-transplant care more convenient and less invasive for the nearly 250,000 people in the United States living with a kidney transplant.

The new test utilizes noninvasive urine sample collection and can produce results within 24 hours. It can detect the CXCL10 chemokine, which may provide valuable information faster than current tests. Elevated urinary CXCL10 levels have been associated with inflammation and early kidney transplant rejection.

Thermo Fisher hopes that the new service will improve current standards of care and provide increased specificity and sensitivity, resulting in fewer unnecessary and invasive biopsies or delayed results. The CXCL10 assay was developed and validated by Thermo Fisher’s One Lambda Laboratories.